医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

BeiGene to Present at Upcoming Investor Conferences

2022年11月04日 PM08:00
このエントリーをはてなブックマークに追加


 

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in two upcoming investor conferences:

  • The 6th Annual Cowen IO Next Virtual Conference on Friday, November 11, at 9:40 a.m. (ET); and
  • The 13th Annual Jefferies Global Healthcare Conference in London on Wednesday, November 16 at 11:25 a.m. (ET).

A live webcast can be accessed from the investors section of BeiGene’s websites at https://ir.beigene.com, https://hkexir.beigene.com and https://sseir.beigene.com. An archived replay will be available for 90 days following the event.

About BeiGene
BeiGene is a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 9,000 colleagues spans five continents, with administrative offices in Beijing, China; Cambridge, U.S.; and Basel, Switzerland. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneGlobal.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221104005187/en/

CONTACT

Investor

Kevin Mannix

+1-857-302-5189

ir@beigene.com

Media

Kyle Blankenship

+1 667-351-5176

media@beigene.com

同じカテゴリーの記事 

  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024